Target product profiles – a lost art?
- February 6, 2018
What do your target product profiles (TPP) say about you? Are you the pragmatist? The dreamer? Or maybe the pessimist? Fortunately, we cannot gauge your personality type from the TPP, or at least we should not be able to. We should, however, be able to understand enough about your product to gauge the potential value […]
New entrants into pharma from the digital sector
- November 27, 2017
Recent times have shown that nothing influences the trajectory of healthcare innovation like the convergence of medicine and technology; but for now, the full potential of this pairing remains to be seen.
When the price…is not right: striving for transparency in drug pricing
- November 13, 2017
For decades, the pharma industry has been at the centre of an incessant debate: transparency in drug pricing. Pharma faces a perpetual paradox of compliance and standardisation on the one hand, and commercial sustainability on the other. Consequently, its drug pricing agenda rides a constant rollercoaster of scrutiny.
Biobetters: Market access opportunity?
- July 14, 2017
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen. For regulatory approval, biobetters must meet the same data requirements as all other originator products, whilst only a reduced clinical data package is needed for biosimilars (Table 1). This produces time pressure for biobetters […]